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Abstract
Introduction
As Novel psychoactive substances (NPS) are conceived to mimic the effects of common
illicit drugs, they represent a serious public health challenge due to the spike in intoxications
and fatalities that have been linked to their use. This study aims to provide epidemiological
data on NPS use in the USA, determining lifetime prevalence of use and defining demo-
graphic, socioeconomic, drug use patterns and mental health correlates.
Methods
This study uses secondary data from the US National Survey on Drug Use and Health
(NSDUH), which is a large cross-sectional population-based survey carried out annually in
the USA. We analysed data from 2007–14 (N = 307,935) using bivariate descriptive analysis
and binary logistic regression to calculate prevalence and determine factors underlying NPS
consumption. Adjusted odds ratios (OR) with 95% CI’s were calculated for a set of selected
independent variables.
Results and discussion
Our analysis NSDUH from 2007–14 highlights an increase in NPS use among adults, espe-
cially among white young men aged 18 to 25. Although the level of education of NPS users
was relatively higher as compared to non-users, NPS users seemed to have a less wealthy
situation. However, socioeconomic vulnerability appeared to be less important than mental
health issues as a correlate to NPS use. NPS users seem to have followed a pattern of
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Data Availability Statement: Data for each year,
respectively, is available from the following URLs: �
2007: https://datafiles.samhsa.gov/study-dataset/
national-survey-drug-use-and-health-2007-nsduh-
2007-ds0001-nid13654 � 2008: http://datafiles.
samhsa.gov/study/national-survey-drug-use-and-
health-nsduh-2008-nid13602 � 2009: http://
datafiles.samhsa.gov/study/national-survey-drug-
use-and-health-nsduh-2009-nid13531 � 2010:
https://datafiles.samhsa.gov/study-dataset/
polysubstance use throughout their life, which involves both traditional illicit drugs and clas-
sic synthetic drugs. As NPS use seemed to be more prevalent among people having mental
health issues, the rise in their use may have a negative impact on population mental health
outcomes.
Conclusion
Further comparative research on trends in NPS use and potential public health responses
would be instrumental for developing appropriate health interventions, including drug check-
ing, education for users and training for healthcare professionals working both within emer-
gency wards and in/outpatient addiction and mental health services.
1. Introduction
Over the last few decades, the emergence of Novel Psychoactive Substance (NPS), sometimes
also called “legal highs”, “research chemicals” or “designer drugs”, has become a topic of inter-
est for researchers, policy officers, healthcare providers and enforcement agencies in high-
income countries [1–9]. NPS are conceived to mimic the pharmacological effects of common
illicit drugs. As a result, a variety of uncontrolled new substances is regularly appearing in the
international drug market to circumvent current drug legislation by continuously changing
their chemical composition [10–14]. The number of NPS identified by authorities worldwide
has increased by more than 400% since 2009. Globally, 950 new substances have been detected
by the end of 2019 (UNODC Early Warning Advisory), of which 790 are already available in
the European market according to the EU Early Warning System [15, 16]. NPS represent a
serious public health challenge due to the lack of awareness of their actual composition, as well
as their potency, effects and risk profile. NPS stimulants and novel synthetic opioids–most of
which are much stronger than morphine–have already been linked to a spike in intoxications
and fatalities in the USA and Europe [17–22]. Although the available epidemiological evidence
on the use of NPS has increased in recent years, knowledge of lifetime prevalence rates is lim-
ited due to the scarcity of relevant population-based surveys with adequate sampling design
[23–39]. We aim to address this gap by putting forth a population-based study assessing life-
time prevalence of NPS use among adults in the USA. Our study utilised secondary data from
the U.S. National Survey on Drug Use and Health (NSDUH), which collects information on
alcohol, tobacco and illegal substance use, misuse of prescription medicines and mental health.
We examined lifetime rates of NPS use between 2007 and 2014, with the aim of evaluating (1)
the socio-demographics characteristics of NPS users, as well as (2) the possible association
between illicit drug use patterns, the (3) mental health needs of this population and (4) the pat-
terns of NPS use and substances preferred by users.
2. Methods
2.1 Sample and procedures
This study analyses secondary data from the NSDUH. It is therefore no primary recruitment
of participants since all data has already been collected nor it is possible to obtain consent
from participants included in this study. Data for adults aged 18 and over were included from
the 2007–14 cohorts of the NSDUH, an annual, cross-sectional population-based survey of
civilian, non-institutionalised individuals (N = 307,935). This eight-year timeframe was chosen
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national-survey-drug-use-and-health-2010-nsduh-
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due to notable changes made to the survey questionnaire and data collection procedures in
2015, affecting comparability over time [40]. The sample strategy for this period consists of a
multistage, deeply stratified area probability sample design. First, census tracts are defined
using equally sized geographical partitions of the 50 U.S. States plus de District of Columbia
(first stage). These areas are then partitioned into smaller geographic areas or “segments” (sec-
ond stage). Afterwards, a number of dwelling units are selected according to a selection rate
based on a state’s population size (third stage). Finally, individuals (fourth stage) are selected
within dwelling units based on five age-group classifications: 12 to 17, 18 to 25, 26 to 34, 35 to
49, and 50 or older. The survey is administered via face-to-face interviews using computer-
assisted interviewing (CAI) and audio computer-assisted self-interviewing (ACASI) to
increase respondents’ cooperation and willingness to report honestly about topics such as illicit
drug use behaviour and mental health issues. Questions pertaining to the use of regulated sub-
stances are self-administered through ACASI [41].
2.2 Demographics
We categorized individuals from the NSDUH according to the following age groups: 18–25,
26–34, 35–49 and 50 years or older. Sex was coded as either Male or Female. Respondent eth-
nic background was coded as White, African American, Hispanic and Other (including Native
American and Asian or Pacific Islander). Education was coded along the following categories:
Elementary (7th grade or less), Secondary (8th to 12th grade), and Post-Secondary (13th grade/
Freshman or higher). Marital status was coded as either Single–including widowed, divorced
and separated–or Married. Metropolitan size was coded as Large, Small or Non-metropolitan
based on 2010 census data and 2009 Core Based Statistical Area classifications provided by the
Office of Management and Budget (OMB) [41].
2.3 Socioeconomic variables
Employment status was categorized as Full-time, Part-time, Not employed (including unem-
ployed and not in labour force). Household annual income was categorised as: less than
$20,000; $20,000 - $49,999; $50,000 - $74,999; $75,000 or more. A dichotomous variable was
created to indicate whether a respondent received any form of government assistance (i.e. sup-
plemental security income, food stamps, cash assistance, and/or non-cash assistance). The
respondent’s primary health insurance was coded as Private, Medicare (covering people aged
65 and older, as well as people with disabilities or chronic health conditions), Medicaid (for
individuals whose resources are insufficient to pay for healthcare regardless of their age), Tri-
care & Veterans Administration (VA) (for military veterans), other, or Uninsured. Addition-
ally, based on the four indicators described above, an aggregate index of socioeconomic
vulnerability was created by summing the number of vulnerability attributes observed (i.e. no
employment, annual income lower than $20,000, no health insurance or eligible for Mediaid,
receiving government assistance). The index values range from 0 (which indicates no vulnera-
bility attributes) to high (when at least 3 vulnerability attributes were observed).
2.4 Use of NPS
We considered lifetime use of 64 NPS as our outcome variable. These substances were sponta-
neously mentioned by respondents through open-ended questions about the recreational use
of (1) prescription drugs (classified by the survey into four categories: pain killers, sedatives,
stimulants and tranquilizers), (2) hallucinogens (other than LSD, PCP, peyote, mescaline, psi-
locybin and ecstasy), (3) inhalants, (4) non-prescription cough or cold medicines and (5) spe-
cial drugs such as injectable stimulants. For the purpose of this study, we defined as NPS
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according to two criteria: 1) their international legal status (substances not classified under
Schedules I and II of the 1971 UN Convention on Psychotropic Substances); 2) their recrea-
tional use among general population, defined by the questions about their consumption for
the experience or feeling they cause (“for kicks or to get high”). A few exceptions to these rules
were made with controlled substances whose recreational use has remained limited until
recently (e.g. Bromo mescaline, Brolamfetamine (DOB), MDA, PMA) (S1 Table).
We listed 63 reported substances and classified them into four NPS categories according to
their pharmacological effects: (1) hallucinogens, (2) stimulants, (3) depressants and (4) syn-
thetic cannabinoids. Among the 64 substances reviewed, we identified 29 phenethylamines (22
hallucinogens and 7 stimulants), 17 tryptamines, 5 synthetic cathinones (including 1 generic
category encompassing three different street names), 3 synthetic cannabinoids (including 1
generic category compassing nine different street names), 2 ergolines, 2 dissociatives, 2 benzo-
diazepines, 1 aminoindane, 1 piperazine, 1 inhalant and 1 synthetic opioid (S1 Table). We sub-
sequently created dichotomous variables indicating lifetime use of at least one substance of
each category. Finally, an aggregate indicator for lifetime NPS use was created based on the
reported use of at least one of the four categories.
2.5 Use of traditional illicit drugs and “classic synthetic drugs”
In order to better characterise the drug use patterns of NPS users, two aggregate dichotomous
variables were created. Similar to the construction of the lifetime NPS use variable, we created
an aggregate indicator for lifetime use of illicit drugs based on the use of at least one of the four
traditional illicit drugs included in the NSDUH. This aggregate indicator was constructed
based on the data collected through the NSDUH core questions on lifetime use of cocaine,
crack, heroin and cannabis. Additionally, an aggregate indicator for lifetime use of “classic syn-
thetic drugs” was also constructed based on the data from NSDUH core questions on lifetime
use of LSD, ecstasy and PCP, as well as the use of so-called (2) “special drugs” such as metham-
phetamine and GHB, as defined by NSDUH [42]. For the purpose of this study, “classic syn-
thetic drugs” were defined as commonly used synthetic psychoactive substances already placed
under international control and whose chemical structures, pharmacology and effects are well
known by the scientific community.
2.6 Past-year mental health
Past-year prevalence of four mental health indicators were included in the study. First, we
used the Serious Psychological Distress variable (SPD), which is based on the Psychological
Distress Scale (K6) that gathers information regarding how frequently individuals experience
symptoms of psychological distress over a time period (e.g. over the past month or over the
worst month of the past year that was not the past 30 days), with values ranging from 0 to 24.
Symptoms of distress include feeling nervous, feeling hopeless, feeling restless or fidgety, feel-
ing so sad or depressed that nothing could cheer one up, feeling that everything was an effort,
and feeling down on oneself, no good, or worthless. For each of these six items, responses of
"all of the time" were coded 4, "most of the time" were coded 3, "some of the time" were coded
2, "a little of the time" were coded 1, and "none of the time" and all other responses were coded
0. These assigned values were summed across the six items to calculate a past month K6 total
score and a K6 score for the worst month of the past year other than the past 30 days. Respon-
dents were classified as having had a past year SPD if their K6 score was 13 or higher (based on
the higher score between the past month K6 total score and the K6 score in the worst month of
the past year other than the past 30 days). Conversely, they are classified as not having had a
past year SPD if their K6 score was lower than 13 [42].
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Second, we used the past-year Major Depressive Episode (MDE) indicator. Respondents
were defined as having MDE in the past year if they had a lifetime MDE and a period of time
in the past 12 months when they felt depressed or lost interest or pleasure in daily activities for
2 weeks or longer, while also having some of the other symptoms for lifetime MDE. Respon-
dents were defined as having had a lifetime MDE if they had five or more of nine symptoms
for MDE in the same 2-week period in their lifetime, in which at least one of the symptoms
was a depressed mood or loss of interest or pleasure in daily activities. Symptoms for MDE
include: (1) depressed mood most of the day; 2) markedly diminished interest or pleasure in
all or almost all activities most of the day; 3) changes in appetite and weight; 4) insomnia or
hypersomnia; 5) psychomotor agitation or retardation; 6) fatigue or loss of energy; 7) feelings
of worthlessness; 8) diminished ability to think or concentrate or indecisiveness; 9) recurrent
thoughts of death or recurrent suicide idea. Respondents with no lifetime MDE or respondents
with lifetime MDE but no period of depression lasting 2 weeks or longer while having other
symptoms were defined as not having past year MDE. It should be noted at this point that the
NSDUH makes no exclusions for MDE caused by medical illness, bereavement, or substance
use disorders [42].
Third, we created an indicator of past-year access to mental health treatment that encom-
passes access to in/outpatient mental health treatment and use of prescription medicine for a
mental health condition [42]. Finally, we use the indicator of "unmet mental health need"
defined by NDSUH as having perceived a need for mental health treatment/counselling that
was not received during the past 12 months [42]. Respondents could agree with multiple diag-
nostic questions, so these indicators are not mutually exclusive. Reasons for not receiving men-
tal health treatment/counselling that was needed in the past year were asked by the NDSUH
through a set of questions, yet they were not included in this study.
2.7 Imputed data
Since 1999, the NSDUH addresses item nonresponse using an imputation method known as
predictive mean neighbourhood (PMN), which is applied in a stepwise fashion: (1) response
propensity adjustment; (2) prediction modelling; and (3) hot-deck imputation [41]. Data
imputation has been extensively used for variables having a larger proportion of missing values
(e.g. ethnicity and government assistance) and slightly less for variables such as education,
marital status, income, and health insurer [41].
2.8 Statistical analyses
All statistical analyses were performed in Stata 14.2. NSDUH datasets from individual years
were combined into a single file for analysis to allow for year to year comparisons. In order to
estimate the annual average of the number of individuals who engaged in a particular behav-
iour based upon pooled data from 2007–14, adjusted analysis weights were created by dividing
annual weights by eight (the number of cohorts under study) according to the NSDUH Public
Use File Codebook [42]. Thus, all analyses used the analytical weights provided with the data-
sets to account for the complex survey design of the NSDUH. We utilised a bivariate descrip-
tive analysis with weighted least squares to investigate how demographics, socioeconomic
characteristics, drug use patterns and mental health were related to NPS use. For the multiple
response NPS variable, the significance of the differences among the proportions of NPS cate-
gories was evaluated through the non-parametric Cochran’s Q test, which yielded highly sig-
nificant differences in the proportions of the four NPS categories (Cochran’s chi2(3) =
1133.129, p<0.01) [43]. In order to identify which factors were more related to NPS use, we
performed a pairwise correlation at p<0.05; yet it appeared that none of the factors had a
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strong correlation with the outcome variable. As a result, we performed a binary logistic
regression for NPS use and a set of independent variables selected upon our previous knowl-
edge of the topic. Adjusted odds ratios (OR) with 95% CI’s were calculated for the selection of
the independent variables included in the model (age, sex, marital status, ethnicity, education,
past-year SPD, MDE, unmet mental health need, access to mental health treatment, lifetime
use of traditional illicit drugs and classic synthetic drugs). As the available epidemiological evi-
dence on the use of NPS is still scarce, one of our objectives was to provide relevant popula-
tion-based data. Hence, we decided to use adjusted odds ratios (OR) as they are commonly
used in epidemiology to compare the relative odds of the occurrence of a particular outcome
(e.g. NPS use), given exposure to a series of variables of interest (e.g. sociodemographics, men-
tal health characteristic, drug use patterns). Although, the 95% confidence interval (CI), used
to estimate the precision of the OR, may not be the most adequate measure of accuracy for the
purpose of this study.
3. Results
3.1 Variations in NPS use over time
Consumption of NPS showed an 167% increase between 2007–14. In 2007, the estimate for
lifetime NPS use among adults was 0.09% (95%; CI = 0.06%-0.16%), while 0.24% (95%;
CI = 0.19%-0.31%) of adults had used an NPS seven years later (Fig 1).
The increase in NPS use was notably led by young people–particularly by those between the
ages of 18 and 25 –whose lifetime prevalence of NPS use exhibited a fourfold increase between
2007–14. The exception to this upward trend was the pattern followed by people between aged
50 or older, whose prevalence of NPS use remained stable at around 0.1% during the same
period (Fig 1).
Regarding the evolution over time by NPS category, it is worth to note that the use of syn-
thetic cannabinoids rose steadily between 2007–2014: it accounted for 0.8% of reports in 2008
(when it was first mentioned by respondents), reaching up to 17.1% in 2014. On the other
hand, the use of hallucinogens and stimulants showed a downward trend during the same
period (-11% and -8% of reports respectively). Meanwhile, the use of depressants remained
stable at around 1% of reports (Fig 2).
Fig 1. Lifetime prevalence of NPS use by age group, 2007–14.
https://doi.org/10.1371/journal.pone.0241056.g001
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3.2 Lifetime use of NPS by drug class
Measures of lifetime NPS use were obtained for four NPS categories. The differences in the
proportions of these categories were highly significant, with hallucinogens being the most fre-
quently reported by NPS users (73.8%), followed by stimulants (13.9%) and synthetic cannabi-
noids (11.7%). The use of depressants (0.6%) appeared to be less widespread among our study
population (Fig 3). The overall estimate of lifetime NPS use for the seven-year period was
0.17% (95% CI = 0.15%-0.19%), which corresponds to 385 thousand NPS users (Table 1).
Fig 2. Evolution of NPS reported use by pharmacological effect, 2007–14.
https://doi.org/10.1371/journal.pone.0241056.g002
Fig 3. Proportion of NPS reported use, by pharmacological effect, 2007–14.
https://doi.org/10.1371/journal.pone.0241056.g003
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Table 1. Lifetime prevalence rate of NPS use among adults by sociodemographic variables, characteristics of Users and Non-users of NPS, 2007–14.
Lifetime Prevalence Rate NPS Users Non-users of NPS
% 95% CI % 95% CI % 95% CI
Overall estimate 0.17 (0.15–0.19)
Unweighted sample n = 837 n = 307 148
Weighted sample n = 385 011 n = 230 802 805
Age
18–25 0.49 (0.43–0.55) 43.12 (37.54–48.87) 14.66 (14.45–14.87)
26–34 0.22 (017–0.28) 20.64 (16.44–25.58) 15.79 (15.58–16.01)
35–49 0.07 (0.05–0.10) 11.43 (7.95–16.16) 27.05 (26.78–27.32)
50 and older 0.1 (0.07–0.14) 24.82 (18.27–32.76) 42.5 (42.08–42.92)
Sex
Male 0.27 (0.23–0.31) 77.34 (71.94–81.96) 48.17 (47.87–48.46)
Female 0.07 (0.06–0.09) 22.66 (18.04–28.06) 51.83 (51.54–52.13)
Ethnicity
White 0.21 (0.19–0.24) 84.54 (77.75–89.54) 67.25 (66.86–67.63)
African American 0.04 (0.02–0.08) 2.67 (1.35–5.20) 11.59 (11.31–11.88)
Hispanic 0.08 (0.06–0.11) 7.25 (5.33–9.78) 14.3 (14.03–14.57)
Other 0.13 (0.05–0.35) 5.54 (2.14–13.59) 6.86 (6.66–7.07)
Marital Status
Single 0.28 (0.25–0.31) 77.21 (70.27–82.93) 46.58 (46.22–46.94)
Married 0.07 (0.05–0.10) 22.79 (17.07–29.73) 53.42 (53.06–53.78)
Metropolitan Area Size
Non-Metropolitan 0.13 (0.08–0.21) 12.83 (8.28–19.35) 16.15 (15.79–16.52)
Small Metropolitan 0.18 (0.15–0.21) 32.52 (28.19–37.18) 30.25 (29.69–30.83)
Large Metropolitan 0.17 (0.14–0.20) 54.65 (48.14–61.01) 53.6 (53.10–54.09)
Education
Elementary 0.02 (0.01–0.06) 0.04 (0.14–1.14) 3.29 (3.15–3.43)
Secondary 0.12 (0.11–0.14) 31.11 (26.99–35.55) 41.52 (41.19–41.85)
Post-secondary 0.21 (0.18–0.24) 68.49 (64.01–72.65) 55.19 (54.84–55.54)
Employment
Full-Time 0.16 (0.14–0.19) 49.94 (44.37–55.51) 51.24 (50.94–51.55)
Part-Time 0.3 (0.23–0.40) 25.29 (19.94–31.50) 13.87 (13.67–14.07)
Not employed 0.12 (0.09–0.15) 24.78 (19.39–31.08) 34.89 (34.57–35.22)
Income
Less than 20,000 0.29 (0.24–0.37) 32.4 (26.83–38.52) 18.29 (17.98–18.61)
20,000 to 49,999 0.13 (0.11–0.17) 26.3 (21.31–31.98) 32.48 (32.18–32.77)
50,000 to 74,999 0.14 (0.10–0.20) 14.89 (10.88–20.04) 17.28 (16.98–17.59)
More than 75,000 0.14 (0.11–0.17) 26.41 (21.61–31.85) 31.95 (31.49–32.42)
Health Insurer
Private 0.15 (0.13–0.17) 59.65 (52.95–66.01) 66.68 (66.29–67.08)
Medicare 0.18 (0.08–0.42) 8.62 (3.73–18.66) 7.84 (7.63–8.06)
Medicaid 0.13 (0.09–0.18) 4.96 (3.50–7.00) 6.46 (6.31–6.60)
Tricare & VA 0.13 (0.06–0.31) 1.41 (0.61–3.21) 1.75 (1.67–1.84)
Other 0.37 (0.21–0.67) 4.12 (2.32–7.21) 1.84 (1.77–1.92)
Uninsured 0.23 (0.18–0.29) 21.23 (16.64–26.68) 15.43 (15.21–15.64)
Receives Government Assistance 0.19 (0.16–0.24) 20.73 (16.64–22.52) 17.84 (17.60–18.09)
Economic Vulnerability
No vulnerability 0.14 (0.11–0.17) 37.48 (31.41–43.97) 45.51 (45.16–45.86)
(Continued)
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3.3 Lifetime prevalence of NPS use and sociodemographic characteristics of
users
According to our results (Table 1), NPS users were mostly white Americans (84.54%; 95%
CI = 77.75%-89.54%), men (77.34%; 95% CI = 71.94%- 81.96%), living on their own (77.21%;
95% CI = 70.27%-82.93%) in large metropolitan areas (54.65%; 95% CI = 48.14%-61.01%).
Most NPS users had college level of education of higher (68.49%; 95% CI = 64.01%-72.65%).
The large majority of NPS users were active workers: 49.94% of them work on a full-time
basis (95% CI = 44.37%-55.51%) and 25.29% had a part-time job (95% CI = 19.94%-31.50%).
As NPS use still was a rare phenomenon during the period under study, comparisons with
non-users of NPS and general population appear to be equivalent.
Table 1. (Continued)
Lifetime Prevalence Rate NPS Users Non-users of NPS
% 95% CI % 95% CI % 95% CI
Overall estimate 0.17 (0.15–0.19)
Unweighted sample n = 837 n = 307 148
Weighted sample n = 385 011 n = 230 802 805
Low (1 attribute) 0.2 (0.15–0.25) 36.29 (28.19–43.10) 29.87 (29.53–30.22)
Moderate (2 attributes) 0.19 (0.14–0.25) 15.79 (11.73–20.91) 13.95 (13.71–14.19)
High (3 or 4 attributes) 0.18 (0.14–0.23) 11.44 (8.51–15.21) 10.67 (10.44–10.91)
Past-Year Serious Psychological Distress
No
Yes 0.42 (0.33–0.52) 26.38 (22.64–27.61) 10.51 (10.35–10.68)
Past-Year Major Depressive Episode
No
Yes 0.45 (0.34–0.58) 18.14 (14.69–19.50) 6.73 (6.60–6.86)
Past-Year Perceived Unmet Mental Health Need
No
Yes 0.51 (0.39–0.65) 15.03 (12.76–16.90) 4.91 (4.80–5.02)
Past-Year Received Mental Treatment
No
Yes 0.32 (0.25–0.41) 26.93 (24.80–32.82) 14.01 (13.80–14.22)
Lifetime use of traditional illicit drugs
No use of traditional illicit drugs
Any traditional illicit drug 0.36 (0.32–0.40) 98.71 (97.38–99.37) 45.41 (45.10–45.73)
Cocaine 0.88 (0.78–1.00) 85.46 (82.43–88.05) 15.97 (15.77–16.18)
Crack 1.28 (1.04–1.57) 29.19 (24.22–34.70) 3.76 (3.65–3.87)
Heroin 2.92 (2.29–3.73) 32.08 (26.04–38.79) 1.78 (1.69–1.87)
Cannabis 0.36 (0.33–0.41) 98.66 (97.31–99.34) 44.99 (44.67–45.30)
Lifetime use of classic synthetic drugs
No use of synthetic drugs
Any classic synthetic drug 1.09 (0.97–1.22) 92.43 (89.56–94.56) 14.02 (13.86–14.18)
LSD 1.35 (1.19–1.52) 82.95 (79.43–85.98) 10.14 (10.00–10.29)
Ecstasy 1.82 (1.60–2.06) 70.41 (63.78–76.27) 6.34 (6.22–6.4)
Methamphetamine 0.67 (0.45–1.00) 8.01 (5.27–12.00) 1.98 (1.90–2.07)
GHB 3.59 (2.73–4.70) 13.14 (10.05–17.00) 0.59 (0.55–0.62)
PCP 1.51 (1.13–2.01) 24.64 (19.28–30.93) 2.68 (2.58–2.79)
https://doi.org/10.1371/journal.pone.0241056.t001
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The proportion of people having a household annual income lower than $20,000 was
slightly higher among NPS users (32.4%; 95% CI = 26.83%-38.52%) than among non-users
(18.29%; 95% CI = 17.98%-18.61%). Similarly, the proportions of people without health insur-
ance (21.23%; 95% CI = 16.64%-26.68%) and receiving government assistance (20.73%; 95%
CI = 16.64%-25.52%) were relatively higher among NPS users as compared to non-users
(15.43%; 95% CI = 15.21%-15.64% and 17.84%; 95% CI = 17.60%-18.09%, respectively). Con-
sequently, the proportion of people showing no factors of socioeconomic vulnerability as
defined by our vulnerability index (cf. 2.3) was lower among NPS users (37.48%; 95% CI =
31.41%-43.97%) than among non-users (45.51%; 95% CI = 45.16%-45.86%). Finally, the use of
NPS was more common among young adults under 35 years old, particularly among those
aged 18 to 25 that represent about 4 in 10 NPS users. Together, young adults aged 18 to 34 rep-
resented 63.76% of NPS users, while they only represented 30.45% of non-users (Table 1). In
addition, the lifetime prevalence rates of NPS use for those age groups– 0.49% (95% CI =
0.43%-0.55%) and 0.22% (95% CI = 0.17%-0.28%) respectively–were higher than the overall
prevalence rate of 0.17% (95% CI = 0.15%-0.19%) (Table 1).
NPS users with the highest level of education were twice more likely to use an NPS
(adjusted OR = 2.46). Conversely, the use of NPS was significantly less likely among people
aged between 35–49 (adjusted OR = 0.14; 95% CI = 0.10–0.21) and among African Americans
(adjusted OR = 0.32; 95% CI = 0.14–0.581) (Table 2).
Different trends in NPS use observed among age groups. The use of hallucinogens was pre-
dominantly reported by people aged 34 or younger, especially by young adults under 25
(78.6% of them reported use of NPS hallucinogens). Meanwhile, the use of stimulants seemed
to be more common among people aged 50 or older (54.7% of them reported use of NPS stim-
ulants). Interestingly, as illustrated by Fig 4, the use of hallucinogens seems to decrease with
age, while the use of stimulants follows the opposite pattern. The use of synthetic cannabinoids
was relatively similar across ages.
3.4 Patterns of illicit drug use among NPS users
As shown in Table 1, 98.71% (95% CI = 97.38%-99.37%) of NPS users had already consumed
at least one of the four most used illicit drugs (e.g. cocaine, crack, heroin and cannabis) in their
lifespan. Cannabis and cocaine were the most common illicit drugs consumed by NPS users:
almost all of them had already used cannabis (98.66%; 95% CI = 97.31%-99.34%) and 85.46%
(95% CI = 82.43%-88.05%) had consumed cocaine at least once in their life (Table 1).
Additionally, 92.43% (95% CI = 89.56%-94.56%) of NPS users had also already used classic
synthetic drugs, particularly LSD (82.95%; 95% CI = 79.43%-85.98%) and ecstasy (70.41%;
95% CI = 63.78%-76.27%). The use of PCP (24.64%; 95% CI = 19.28–30.93%), GHB (13.14%;
95% CI = 10.05–17.00%) and methamphetamine (8.01%; 95% CI = 5.27–12.00%) appeared to
be less common among NPS users (Table 1). Overall, NPS users seemed to have followed a pat-
tern of polysubstance use throughout their life, which involves both traditional illicit drugs
and classic synthetic drugs.
Overall, people having already tried at least one classic synthetic drug in their life were
28.44 times more likely to use an NPS (95% CI = 19.36–41.77, p< 0.000) and those that had
used traditional illicit drugs were 7.67 times more likely to do so (95% CI = 3.46–16.88,
p< 0.000) (Table 2).
3.5 Use of NPS and mental health
NPS use seemed to be more frequent among adults who had experienced mental health prob-
lems. While the overall estimate of lifetime NPS use for adults was 0.17%, it reached 0.42%
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Table 2. Unadjusted and adjusted binary logistic regression of factors associated with NPS use among adults in the USA, 2007–14.
Unadjusted Adjusted (a)
OR 95% CI p-Value OR 95% CI p-Value
Age
18–25 1 1
26–34 0.44 0.34–0.58 <0.001 0.34 (0.25–0.46) <0.001
35–49 0.14 0.10–0.21 <0.001 0.14 (0.10–0.21) <0.001
50 and older 0.20 0.13–0.29 <0.001 0.33 (0.23–0.49) <0.001
Sex
Female versus Male 0.27 0.20–0.36 <0.001 0.34 (0.25–0.46) <0.001
Marital Status
Married versus Single 0.26 0.18–0.37 <0.001 0.54 (0.38–0.77) 0.01
Ethnicity
White 1 1
African American 0.18 0.09–0.37 <0.001 0.32 (0.14–0.58) 0.002
Hispanic 0.40 0.29–0.57 <0.001 0.56 (0.37–0.74) 0.001
Other 0.64 0.24–1.75 0.382 0.97 (0.34–2.76) 0.950
Metropolitan Area Size
Non-Metropolitan 1
Small Metropolitan 1.35 0.84–2.18 0.209
Large Metropolitan 1.28 0.76–2.16 0.343
Education
Elementary 1 1
Secondary 6.17 2.14–17.81 0.001 1.29 (0.43–3.82) 0.645
Post-secondary 10.22 3.52–29.70 <0.001 2.46 (0.82–7.36) 0.105
Employment
Full-Time 1
Part-Time 1.87 1.38–2.53 <0.001
Not employed 0.73 0.54–0.99 0.041
Income
Less than 20,000 1
20,000 to 49,999 0.46 0.33–0.64 <0.001
50,000 to 74,999 0.49 0.33–0.72 0.001
More than 75,000 0.47 0.34–0.63 <0.001
Receives Government Assistance
Yes versus no 1.20 0.92–1.58 0.174
Health Insurer
Private 1
Medicare 1.23 0.51–2.99 0.647
Medicaid 0.86 0.59–1.26 0.434
Tricare & VA 0.90 0.38–2.11 0.800
Other 2.50 1.38–4.54 0.003
Uninsured 1.54 1.16–2.05 0.003
Economic Vulnerability
No vulnerability 1
Low (1 attribute) 1.43 1.01–2.03 0.042
Moderate (2 attributes) 1.37 0.97–1.95 0.074
High (3 or 4 attributes) 1.30 0.91–1.86 0.143
Past-Year Serious Psychological Distress
(Continued)
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(95% CI = 0.33%-0.52%) among adults who experienced serious psychological distress (SPD)
in the last year and 0.45% (95% CI = 0.34%-0.58%) among those who had a major depressive
episode (MDE). Moreover, the estimate for lifetime NPS use was 0.32% (95% CI = 0.25%-
0.41%) for adults who received mental health treatment during the last year, while it was
Table 2. (Continued)
Unadjusted Adjusted (a)
OR 95% CI p-Value OR 95% CI p-Value
Yes versus no 3.05 2.29–4.07 <0.001 1.14 (0.80–1.63) 0.454
Past-Year Major Depressive Episode
Yes versus no 3.07 2.23–4.24 <0.001 1.37 (0.90–2.0) 0.137
Past-Year Perceived Unmet Mental Health Need
Yes versus no 3.43 2.59–4.54 <0.001 1.29 (0.89–1.86) 0.177
Past-Year Received Mental Treatment
Yes versus no 2.26 1.70–3.01 <0.001 1.31 (0.94–1.81) 0.107
Lifetime use of traditional illicit drugs
Yes versus no 91.93 44.64–189.30 <0.001 7.67 (3.49–16.88) <0.001
Cocaine 30.92 24.69–38.72 <0.001
Crack 10.56 8.21–13.57 <0.001
Heroin 26.10 19.33–35.25 <0.001
Cannabis 90.22 44.20–184.18 <0.001
Lifetime use of classic synthetic drugs
Yes versus no 74.88 52.72–106.35 <0.001 28.44 (19.36–41.77) <0.001
LSD 43.11 34.34–54.12 <0.001
Ecstasy 35.13 26.04–47.39 <0.001
Methamphetamine 4.30 2.76–6.71 <0.001
GHB 25.55 18.68–34.94 <0.001
PCP 11.87 8.69–16.21 <0.001
(a) Adjusted binary logistic regression for age group, sex, ethnicity, marital status, education, past-year experience of SPD, MDE, unmet mental health need, access to
mental health treatment, and lifetime use of traditional illicit drug and classic synthetic drug
https://doi.org/10.1371/journal.pone.0241056.t002
Fig 4. NPS reported use by pharmacological effect and age group, 2007–14.
https://doi.org/10.1371/journal.pone.0241056.g004
PLOS ONE Illicit drug use and poor mental health linked to lifetime prevalence of NPS use among adults in the USA
PLOS ONE | https://doi.org/10.1371/journal.pone.0241056 October 30, 2020 12 / 18
0.51% (95% CI = 0.39%-0.65%) among those that had perceived an unmet mental health need
(Table 1).
As shown in Table 2, adults experiencing mental health problems were more exposed to
NPS use: adults who had had a MDE over the last 12 months were 1.36 times more likely to
have used an NPS (95% CI = 0.90–2.00), while those who experienced SPD in the last year
were 1.14 times more likely to have used an NPS (95% CI = 0.80–1.63). Finally, adults with
unsolved mental health issues were 1.29 times more likely to have used NPS (95% CI = 0.89–
1.86), while those who received mental health treatment were 1.31 times more likely to have
used an NPS (95% CI = 0.94–1.81).
4. Discussion
According to our findings, the lifetime prevalence of NPS use increased between 2007–14,
especially among young adults aged 18 to 25. Although the level of education of NPS users was
relatively higher as compared to non-users (or general population), NPS users seemed to have a
less wealthy situation. NPS users seemed to have followed a pattern of polysubstance use
throughout their life, particularly of cannabis, cocaine and classic synthetic drugs. This is consis-
tent with findings from prior international studies that have already pointed out patterns of
polysubstance use among NPS users [11]. As most of the NPS emulate the effects of classic syn-
thetic drugs (e.g. LSD, ecstasy, PCP), their use may be considered as a contributing factor to
NPS use. Our study shows that NPS use seems to be more prevalent among people having men-
tal health problems, which is also consistent with prior studies in the field that point to a higher
prevalence of NPS use among psychiatric patients, with NPS users being also more likely to
require intensive psychiatric care. Moreover, clinical case studies have suggested that the use of
synthetic cannabinoids may trigger or aggravate psychotic episodes [44–47]. Considering that
scientific evidence has already suggested a bidirectional association between psychotic experi-
ences and selected substance use disorders, the rise in NPS use may have a negative impact on
population mental health outcomes [48–50]. As affordability issues are the most frequently
mentioned reasons for not receiving mental health services in the USA [51], the association
between NPS use and mental health is particularly worrying, especially taking into account the
higher proportion of NPS users that declared an unmet mental health need and their relative
more precarious socioeconomic situation as compared to non-users. Yet socioeconomic vulner-
ability appeared to be less important than mental health issues as a correlate to NPS use, as life-
time prevalence of NPS use did not vary according to composite levels of wealth.
The profile of NPS users that may be addressed based on the results of our study (highly
educated young adults, economically active yet relatively unprivileged, presenting higher levels
of mental health issues than the general population) seem to be concordant with results from
recent studies conducted in Europe among NPS users that identify young active workers using
NPS to cope with their daily life challenges and dealing with health issues as one of the various
profiles of NPS users [52–54].
It is noteworthy to emphasise a few limitations of this study. First, the overall objective of
the NSDUH is to provide data on the level and patterns of alcohol, tobacco and illegal sub-
stance use and misuse, while the present study particularly aimed to look at the use of NPS
based on the data obtained through open-ended questions. In addition, commonly used data
collection strategies are known to be inefficient for rare events data such as NPS use, while sta-
tistical procedures such as logistic regression, can considerably underestimate the probability
of rare events [55]. Hence, most of results obtained through this study are not statistically sig-
nificant yet they give a valuable input for the study of NPS use as they come from one of the
few population-based data sources currently available.
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Second, the use of self-reported substance use as an outcome variable may have led to sig-
nificant levels of mis/underreporting due to the diversity of substances currently available in
the drug market (some of whom may have not been reported at all), the variety of nomencla-
tures associated with them, and the lack of awareness among respondents of the actual chemi-
cal composition of the substances they used. Furthermore, the design of the NSDUH as a
household survey does not permit sampling of homeless or institutionalized persons, who
show specific patterns of problematic drug use [56, 57]. Finally, the use of a repeated, cross-
sectional survey provides data about how NPS use has changed over time at a societal level.
Unlike a longitudinal study, it does not allow for an assessment of individuals over time and,
consequently, relationship cannot be established between the outcome variable and the expo-
sures of interest [58]. Although these findings do not forcibly reflect the current epidemiologi-
cal correlates of NPS use in the USA, they do provide valuable data on its early stage of
development and may inform public health authorities about the main sociodemographic,
mental health and drug use patterns of NPS use among adult population.
5. Conclusion
The increase in NPS consumption observed over the last decade has raised public health con-
cern about the risks related to the consumption of new substances whose actual origin and
composition remained widely unknown. The emergence of NPS is particularly worrying given
the scarcity of evidence around the pharmacology and potential toxic effects of new psychoac-
tive substances regularly appearing in the international drug market. Although the coexistence
of both problematic drug use and mental health issues is a well-known phenomenon within
the scientific community, in the USA this new trend in drug use is of particular interest con-
sidering that the proportion of reported unmet mental health need seems to be higher among
NPS users as compared to non-users. Further comparative research on trends in NPS use and
potential policy public health responses would be instrumental for developing appropriate
health interventions, including drug checking, education for users and training for healthcare
professionals working both within emergency wards and in/outpatient addiction and mental
health services.
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